Full-Time

Head of DMPK

Recursion

Recursion

501-1,000 employees

Data-driven drug discovery platform leveraging datasets

Compensation Overview

$321.8k - $443.1k/yr

+ Bonus + Equity compensation

Salt Lake City, UT, USA + 1 more

More locations: New York, NY, USA

Hybrid

Office-based, hybrid; 50% in-office required.

Category
Biology & Biotech (1)
Required Skills
Data Science
Machine Learning
Pharmacology

Get referred to Recursion

See people who can refer or advise you

Requirements
  • You hold a PhD (or equivalent) in Pharmacokinetics, Drug Metabolism, Pharmacology, or a related field.
  • You have a proven track record of moving multiple programs from Discovery into Development (typically 15+ years) in the pharmaceutical or biotech industry.
  • You are comfortable working at the intersection of biology and technology.
  • You are cautiously optimistic that data-driven, computational approaches are the future of drug discovery.
  • Deep expertise in small molecule DMPK is essential. Experience with related modalities (ADCs, proximity-inducing or peptides) is a distinct advantage.
  • You are intimately familiar with IND submission requirements and have a history of successfully navigating regulatory interactions.
  • You value "One Team" over silos. You are known for strong, transparent working relationships and the ability to influence cross-functional stakeholders.
  • Expertise in in vitro and in vivo ADME as well as contemporary PK/PD modeling. Extending to the properties and data sets commensurate with CNS exposure (or conversely restricting exposure to peripheral tissues).
  • Experience with human PK and efficacious dose prediction.
  • Proficiency in managing CROs to ensure high-quality data and timely delivery.
  • Knowledge of biotransformation and metabolic pathways.
  • Extensive experience in working with external collaborators in all shapes and forms (CROs, SMEs, Large Pharma)
Responsibilities
  • Define and execute the overarching DMPK strategy for a diverse therapeutic area portfolio, primarily focused on small molecules with the agility to support emerging modalities (e.g. peptides, ADCs, proximity-inducing therapeutics).
  • Ensure high degree of scientific excellence as programs move from early discovery into development ensuring robust human dose projections, DDI assessments, and supporting translational PK/PD strategies.
  • Partner with Data Science and ML teams to refine predictive ADME models, transforming how we prioritize compounds and de-risking the portfolio.
  • Act as a strategic subject matter expert for high-stakes external partnerships by collaborating with internal scientific leaders and external counterparts with transparency and technical rigor.
  • Develop and lead a high-performing team. You won't just manage - you will amplify the talents of your team, fostering an environment of active learning and rapid adaptation.
  • A critical component of multidisciplinary project teams. A critical partner to Toxicology, Translation and Design ensuring that DMPK insights are integrated into the earliest stages of target validation and lead optimization.

Recursion uses hardware, software, and data to accelerate drug discovery in the TechBio space, running thousands of wet-lab experiments weekly to profile genes and compounds across many cell types. It combines a massive proprietary dataset (about 50 petabytes) with a powerful computing platform, BioHive 1, to map billions of gene–compound relationships and generate actionable drug candidates. Its approach blends high-throughput experimentation with large-scale data science to create learning loops and partnerships with pharmaceutical companies, research institutions, and healthcare providers. Its goal is to decode biology at scale and discover and commercialize medicines that can improve patient lives.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Salt Lake City, Utah

Founded

2013

Get referred to Recursion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • REC-4881 achieved 53% median polyp reduction at Week 25, validating the AI platform clinically.
  • FDA Fast Track and Orphan Drug designations accelerate the regulatory pathway for REC-4881 in FAP.
  • $665.2 million cash runway supports operations into early 2028 despite recent revenue declines.

What critics are saying

  • Roche partnership completion caused a 56% Q1 2026 revenue drop, exposing acute customer concentration risk.
  • $378.3 million negative free cash flow in FY 2025 creates existential dilution risk if Phase 3 fails.
  • Schrödinger's $255.9 million revenue and positive cash flow expose Recursion's inferior unit economics.

What makes Recursion unique

  • Recursion OS integrates biology, chemistry, automation, and AI to industrialize drug discovery at scale.
  • The company generates 50 petabytes of proprietary data via 2.2 million weekly wet lab experiments.
  • BioHive 1 supercomputer processes six trillion gene-compound relationships within the custom Recursion Map.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Hybrid Work Options